Viropharma Announces Completion Of Enrollment In Phase 3 Study Of Maribavir In Stem C

Dr.AhmadDr.Ahmad مدير عام
تم تعديل 2008/05/31 في مواضيع طبية غير مصنفة
ViroPharma Incorporated (Nasdaq: VPHM) announced that it completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients. This international Phase 3 study is evaluating the efficacy, safety and tolerability of prophylactic use of maribavir administered orally for up to 12 weeks for the prevention of cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT).

أكثر...